The latest price target for Opus Genetics (NASDAQ:IRD) was reported by HC Wainwright & Co. on December 12, 2024. The analyst firm set a price target for $8.00 expecting IRD to rise to within 12 months (a possible 607.96% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Opus Genetics (NASDAQ:IRD) was provided by HC Wainwright & Co., and Opus Genetics reiterated their buy rating.

There is no last upgrade for Opus Genetics

There is no last downgrade for Opus Genetics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Opus Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Opus Genetics was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

While ratings are subjective and will change, the latest Opus Genetics (IRD) rating was a reiterated with a price target of $8.00 to $8.00. The current price Opus Genetics (IRD) is trading at is $1.13, which is out of the analyst’s predicted range.